Institut National de la Santé et de la Recherche Médicale (INSERM)

CIC and U 1116


Faiez Zannad
Professor of Therapeutics and Cardiology, Head of CIC


Hôpital Brabois
Bâtiment Louis mathieu
54500 Vandoeuvre-Les-Nancy

Tel : +33 3 83 15 73 22
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.


Faiez Zannad is Professor of Therapeutics and Cardiology. He is at the Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU) of Nancy since 1995.
He entered the European Society of Cardiology (ESC) in 1996 and is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension. As the Coordinator of French Cardiovascular Clinical Investigation Centres, he has participated in various famous large scale trials in human cardiology such as RALES,VALIANT, CIBIS, CAPRICORN, EPHESUS or EMPHASIS-HF. In these trials, he has been involved either as a member of the Steering Committees or in the Protocol Writing Groups.
He is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.

Complete Curriculum

Inserm U744 – Institut Pasteur de Lille


Florence Pinet
Research Director


Inserm U744 – Institut Pasteur de Lille
1 rue du professeur Calmette
59019 Lille cedex 


Tel : + 33 (0)3 20 87 72 15
Fax : +33 (0)3 20 87 78 94
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.

The research project of our group is translational with the aim to find new biomarkers of abdominal aortic aneurysm (AAA) and of left ventricular remodeling (LVR) post-myocardial infarction and heart failure (HF). The team has expertise on coordinating recruitment of patients with cardiac disorders, clearly phenotyped for AAA (LILAS and CORONA studies), LVR (REVE 1 and REVE 2 studies) or HF (PTHF and INCA studies). We have the expertise in discovery and validation of targets from proteomic (SELDI-TOF, 2D-DIGE, multiplex, ELISA) and miRNAomic (arrays, Q-PCR). Two approaches are currently developped: a clinical approach with the purpose to develop clinical diagnostic applications and a molecular approach with the purpose to understand the mechanisms underlying the targets (proteins, post-translational modified proteins, miRNA) modulation in the pathologies studied.


Lamblin N, Ratajczak P, Hot D, Dubois E, Chwastyniak M, Beseme O, Drobecq H, Lemoine Y, Koussa M, Amouyel P, Pinet F. (2010) Profile of macrophages in human abdominal aortic aneurysms: a transcriptomic, proteomic and protein array study. J. Proteome Res. 9: 3720-3725.


Dubois E, Richard V, Mulder P, Lamblin N, Drobecq H, Henry JP, Amouyel P, Thuillez C, Bauters C, Pinet F. (2011) Decreased Serine207-phosphorylated of troponin T as a biomarker for left ventricular remodeling after myocardial infarction. Eur. Heart J. 32:115-123.


Lamblin N, Bauters A, Fertin M, de Groote P, Pinet F, Bauters C. (2011) Circulating levels of hepatocyte growth factor and left ventricular remodeling after acute myocardial Infarction (from the REVE-2 study). Eur J Heart Failure 13(12):1314-22.


Acosta-Martin A, Panchaud A, Chwastyniak M, Dupont A, Juthier F, Gauthier C, Jude B, Amouyel P, Goodlett DR, Pinet F.(2011) Quantitative mass spectrometry analysis using PAcIFIC for the identification of plasma diagnostic biomarkers for abdominal aortic aneurysm. PLOS One 6(12) :e28698


Boytard L, Spear R, Chinetti-Gbaguidi G, Acosta-Martin AE, Vanhoutte J, Staels B, Lamblin N, Amouyel P, Haulon S, Pinet F. (2013) Role of proinflammatory CD68+MR- macrophages in peroxiredoxin-1 expression and in abdominal aortic aneurysms in humans. Arterioscler. Thromb. Vasc. Biol. . 33:431-8.


Bauters C*, Kumarswamy R*, Holzmann A, Bretthauer J, Anker S, Pinet F*, Thum T*. (2013) Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol Jan 21 [Epub ahead of print].


Gwinner F*, Acosta-Martin A*, Boytard L, Chwastyniak M, Beseme O, Drobecq H, Duban-Deweer S, Juthier F, Jude B, Amouyel P, Pinet F*, Schwikowski B*. Identification of additional proteins in differential proteomics using protein interaction networks. Proteomics 2013 Feb 5. [Epub ahead of print].






Philippe Rouet, PhD
Director of Research

Institut de Médecine Moléculaire de Rangueil, UMR INSERM 1048
Avenue J. Poulhès, BP 84225,
CP31432, Toulouse Cedex 4

@ : This email address is being protected from spambots. You need JavaScript enabled to view it.

Since 2007 : Head of team 7 “Obesity and heart failure: molecular and clinical investigations at The National Institute of Health and Medical Research (INSERM UMR U1048) Toulouse, France.


Obesity is associated with enhanced mortality risk and cardiovascular morbidity. Frequent association of adipose tissue adipokines secretions dysregulations with arterial hypertension promotes myocardial remodeling and heart failure (HF) development. Dr Rouet and his team studied the heart transcriptome regulations, specific to obesity and diabetes. This approach led to the discovery of number of genes encoding for unknown proteins that are under characterization.


Using functional genomic, proteomic and metabolomic and transgenesis approaches we wish to answer to the following questions :

  1. What are the functions of the new obesity/diabetes-regulated genes in heart ?
  2. What are the biomarkers for asymptomatic left ventricular dysfunction (ALVD) and Heart failure diagnosis/prognosis (HF) ? The search for such biomarkers is of major importance in human health, treatment of obese individuals and for detection of very early stages of HF. Using microarrays gene expression profiling,  CE-MS and LC/MSMS proteome analysis and NMR metabolites profiling, we investigate for HF diagnosis and prognosis biomarkers.    

Scientific council member :

  • INSERM national specialized scientific evaluation committee # 4 (cardiology, metabolism, nutrition, reproduction) 2007-12.
  • French National Research Agency (2013-16)
  • External expert for: National Clinical Programs, The Austrian National Science Foundation, The Mount Sinaï Medical School (New York).

Ad Hoc Reviewer for the following Journal

American Journal of Physiology, Physiol. Genomics, Hypertension, PLoS One, Physiological Acta, Int. Journal of obesity. Proteomics, J. Prot. Research, Obesity…

Member of the editorial board of « The open biology Journal »

Academic editor for PloS ONE.

Scientific organizations :

  • Member of the:
    • Groupe de Réflexion sur la Recherche Cardiovasculaire (GRRC).
    • French metabolomics and fluxomics network.
    • European Society of Cardiology, Heart failure association.
    • French Society of Cardiology.





Alexandre Mebazaa
PUPH, Université Paris 7


Hopital Lariboisière
2 rue Ambroise Paré

75010 Paris 


@ :  This email address is being protected from spambots. You need JavaScript enabled to view it.




Marie-Alix Fauvel HOMAGE  


Marie-Alix Fauvel

Project Manager

Inserm Transfert
Paris Biopark
7 rue de watt 
75103 Paris

Tel : +33 (0)1 55 03 01 58
Fax : +33 (0)1 55 03 01 60
@ :  This email address is being protected from spambots. You need JavaScript enabled to view it.


Marie-Alix graduated from Sciences-Po Lille and holds a master degree in European Affairs. She then  enjoyed a first experience at EDF R&D, the research center of the French leading electrical company, where she was tasked with supporting and boosting engineers’ participation in European research programs. She then worked as European Project Manager at CNRS as part of the coordination team of New INDIGO (INCO-FP7- 2.5 M€ - 18 partners) where she acquired extensive knowledge in managing European projects. She is fluent in French and English. She joined Inserm Transfert in 2014 as part of the group for cardiovascular and metabolic diseases within the Department of European Affairs.



Stéphanie Grojean

Global Manager


Stéphanie Grojean is the global manager of EDDH-Fondation Transplantation, an academic Clinical Research Organization in Vandoeuvre les Nancy.
She has a PhD in cellular Biology. She began working at Clinical Investigation Center from the University Hospital of Nancy, before moving into EDDH.
She has over 10 years of the clinical research experience. She had provided clinical management support across many trials, and participated to 3 european research programs before HOMAGE project.



Heicko Breek


ACS Biomarker Office
Oxfordlaan 70

6229 EV Maastricht

The Netherlands


@ : This email address is being protected from spambots. You need JavaScript enabled to view it.



Before joining ACS Biomarker, Heico Breek held senior management positions in both Europe and the United States at Sanofi-Aventis as Vice-President Global Marketing. He was General Manager of Aventis AB in Sweden until he moved to the biotech industry in 2004. He then joined Tigenix NV, a Belgian biomedical company active in the field of Regenerative Medicine as Chief Commercial Officer.

Heico holds a Medical Degree from the VU University Amsterdam and an executive MBA.




Joost Leenders
Project Leader miRNA R&D


ACS Biomarker Laboratory
Meibergdreef 39

1105 EV Amsterdam

The Netherlands


Tel : +31 (0)206971087

@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  



Joost Leenders holds a master's degree in Health Sciences from Maastrich University (NL) and subsequently worked as researcher in the Murdoch Childrens Research Institute in Melbourne, Australia. In 2012, he got his PhD on the molecular causes of heart failure.



 Jim Curry randox  

Jim Curry
Laboratory Manager


Randox Testing Services
34 Diamond Road
Co. Antrim
United Kingdom
BT29 4QX

Tel: +44 (0) 28 9442 2413
Fax: +44 (0) 28 9445 2912
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.





Prof. Dr. Burkert Pieske, FESC, FAHA, FACC


Charité- Berlin
Department of Cardiology

CharitePlatz 1,

10117 Berlin



@: This email address is being protected from spambots. You need JavaScript enabled to view it.

Professor of Cardiology

Director of the Department of Cardiology  at Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum,

Director of the Department of Cardiology  at the German Heart Institute Berlin



Professor Burkert Pieske is Director of the Department of Cardiology at Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, and Director of the Department of Cardiology at the German Heart Institute Berlin. His research focuses on molecular and cellular mechanisms, diagnosis and therapy of heart failure and arrhythmias. Professor Pieske serves as principal investigator or member of steering committees in a number of phase II and phase III clinical trials, and is partner in several European research networks with focus on heart failure, atrial fibrillation, and biomarkers. His current focus is on new diagnostic approaches and novel therapies for heart failure with preserved ejection fraction. 



Recent publications :
Edelmann F,…Pieske B. Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction: The Aldo DHF Trial.  JAMA 2013; in press


Solomon SD, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380:1387-1395






Mamas Mamas
Professor of Cardiology 


Research Institute for Science & Technology in Medicine
Guy Hilton Research Centre
Thornburrow Drive


@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  


Prof. Mamas Mamas was appointed to his post as Professor of Cardiology at Keele University in 2015 and is also honorary Professor of Cardiology at the University of Manchester.  He trained in Medicine at the University of Oxford undertaking a M.A. in Physiological Sciences in 1994 and deferred entry into Clinical School so that he could complete a D.Phil. in Physiological sciences funded by the British Heart Foundation (1994-1997) to study the influence of substances derived from the endocardium on cardiac function. He completed his clinical training at the University of Oxford in 2000 and undertook house jobs in Oxford in the Nuffield Department of Medicine and Cardiology. He completed his Senior House Officer posts at the Royal Brompton Hospital and The Hammersmith Hospital in London, followed by a year at the Royal Salford Hospital.  He was appointed to a national training number in cardiology in the North West Deanery (2004) and was subsequently appointed as clinical lecturer in cardiology (2006). He has a particular interest in the management of abnormalities in glucose tolerance and diabetes in patients with heart failure. His research interests include the application of metabolomics to cardiovascular disease and in particular heart failure which he undertook a 1-year sabbatical at the laboratories of Professor Roy Goodacre at the Manchester Interdisciplinary Biocentre to study the mechanisms of adverse left ventricular remodelling post myocardial infarction and identified novel metabolites that may contribute to the pathophysiology of heart failure development.




Javier Díez, MD, PhD

Avd. Pío XII, 55 | E-31008




Tel : +34 948 194 700

@ :  This email address is being protected from spambots. You need JavaScript enabled to view it.  



Full Professor of Cardiovascular Medicine, School of Medicine, University of Navarra

Director, Division of Cardiovascular Sciences, Centre for Applied Medical Research

Consultant and Chief, Area of Molecular Cardiology, Department of Cardiology and Cardiovascular Surgery, University Clinic.

Pamplona, Spain


Javier Díez was born in Logroño (La Rioja, Spain). He is married and has two children.


Dr. Díez graduated in Medicine at the Medical School of the Autónoma University of Madrid, in 1976, and holds a certificate of Nephrology and Internal Medicine at the University Clinic of the University of Navarra, in Pamplona, in 1982. He next became a research fellow at the Necker Hospital, Paris, from 1982 to 1984, and at the Brigham and Women’s Hospital, Boston, in 1985, where he trained in cardiovascular biology. On his return to Spain he served as Professor of Medicine at the University of Zaragoza before returning to the University of Navarra where he obtained a tenured position at the University Clinic and soon became head of a research unit at the School of Medicine. In 2002 he was appointed as Professor of Vascular Medicine at the School of Medicine of the University of Navarra and in 2009 as Full Professor of Cardiovascular Medicine of the same institution. At present, he is the Director of a division of about 50 clinicians and scientists focused on cardiovascular translational research in the Centre for Applied Medical Research, and Chief of Molecular Cardiology at the University Clinic.


Dr Díez’s main research interest is focused on the mechanisms of myocardial remodeling involved in hypertensive heart disease and heart failure. In addition, his work is also aimed to identify circulating biomarkers of myocardial remodeling potentially useful in the cardiac assessment of hypertensive patients. Dr. Díez’s work has contributed to reveal the non-hemodynamic actions of losartan involved in its organ-protective effects in arterial hypertension. His interest extends also to the molecular basis of oxidative stress that made patients with arterial hypertension prone to develop end-organ damage and atherosclerosis.


Dr Díez is author of 290 scientific papers in leading international journals as well as more than 65 chapters in international books. He is currently a member of the Editorial Board of several journals including Hypertension, Journal of the American Society of Hypertension, Cardiovascular Research, Journal of Molecular and Clinical Pathology, Journal of Heart Disease, The Open Heart Failure Journal, High Blood Pressure & Cardiovascular Prevention, World Journal of Cardiology, and Therapeutic Advances in Cardiovascular Disease. He is also a member of various national and international clinical and scientific societies.


Recently, Dr Díez has served as councillor of the European Society of Clinical Investigation, and he is currently member of the Scientific Committees of four European Union Research Programs, and the Spanish Network for Cardiovascular Research. He is also the past President of the National Commission for Cardiovascular Diseases of the Spanish Ministry of Science and Innovation, and the current President Comission for Extramural Research Evaluation of the National Centre for Cardiovascular Research.


Dr. Díez has been recipient of several awards from international (i.e., European Society of Hypertension) and national (i.e., Spanish Society of Hypertension) scientific societies during the last years.



Arantxa González Miqueo, PhD


Avd. Pío XII, 55 | E-31008




Tel : +34 948 194 700

@ :  This email address is being protected from spambots. You need JavaScript enabled to view it.


Arantxa González Miqueo finalized her degree in Biochemistry in 1999 (1st National Award from the Ministry of Science and Education, Spain). She obtained her PhD in the University of Navarra in 2003, where she studied the involvement of myocardial apoptosis in the development of heart failure related to hypertensive heart disease under the supervision of Prof. Díez and Dr. Fortuño. She completed her postdoctoral training with Professors Piero Anversa and Annarosa Leri at the New York Medical College (New York, USA) and the Brigham and Women’s Hospital (Boston, USA) analysing the role of resident cardiac stem cells in myocardial regeneration. In 2005 she was granted the Norman R. Alpert Award from the European Society on Cardiology and the American Heart Association.


Currently she works as staff scientist in the Division of Cardiovascular Sciences and she is Associate Professor of the School of Medicine (University of Navarra). Additionally, she is a researcher from the Ramón y Cajal Program (2010) from the Ministry of Science and Innovation (Spain) and obtained the certification as researcher of the i3 Program (2010) from the Ministry of Science and Innovation (Spain) and the Government of Navarra (Spain).



She has participated in over 60 papers published in different high impact scientific journals within the cardiovascular field. She has been involved in several competitive research National projects  and in different  European projects within FP6 and FP7.


Her studies are focused in the analysis of the mechanisms involved in myocardial remodelling, namely of the extracellular matrix, which plays a major role in the evolution of heart failure, as well as in the search for non-invasive circulating biomarkers of remodelling.



Kenneth McDonald, MD

Clinical Professor of Medicine

Consultant Cardiologist

St. Vincent’s University Hospital

University College Dublin

Dublin 4


@: This email address is being protected from spambots. You need JavaScript enabled to view it.


Professor Ken McDonald is the founder and Medical Director of the Heart Failure Unit at St Vincent’s University Hospital, Dublin, and is presently the National Clinical Lead for Heart Failure in Ireland.  He is also the Principle Investigator of the Chronic Cardiovascular Disease Management Group and has published in excess of 100 peer reviewed articles. In addition to the clinical services provided to over 4000 patients with or at-risk of heart failure, Professor Ken McDonald has an active research programme that aims to unlock the diagnostic and therapeutic potential of a number of markers of fibrosis and inflammation in left ventricular dysfunction and heart failure. The Unit also has a unique prospective programme evaluating biomarker risk stratification and long term follow up of patients with Stage A/B heart failure.



John Cleland
Professor and Chair of Cardiology

Head of the Academic Unit of Cardiology

Castle Hill Hospital,
Castle Road, Kingston-upon-Hull,
HU16 5JQ,
United Kingdom


Tel : +44 (0)1482 461 776
Fax : +44 (0)1482 461 779

@ : This email address is being protected from spambots. You need JavaScript enabled to view it.


Professor John Cleland qualified in medicine in 1977 at the University of Glasgow. After a period of postgraduate training and an introduction to research he was appointed from 1986-1994 first as a Senior Registrar and subsequently as Senior Lecturer in Cardiology and Honorary Consultant Cardiologist at St Mary’s Hospital, Paddington and the Hammersmith Hospital, London. In 1994 Professor Cleland was awarded a Senior Research Fellowship by the British Heart Foundation to transfer to the Medical Research Council’s Clinical Research Initiative in Heart Failure. Professor Cleland was appointed to the Foundation Chair of Cardiology at the University of Hull in 1999.


Professor Cleland’s main field of interest is in heart failure, extending from its epidemiology, detection and prevention, through the development and implementation of guidelines for the application of current knowledge, to large randomised trials to study new (and old) treatments heart failure.


Particular current interests include the role of myocardial hibernation contributing to heart failure and its treatment (including beta-blockers and revascularisation), ‘diastolic’ heart failure, vascular dysfunction, the potential deleterious effect of aspirin in heart failure, ventricular resynchronisation, telemonitoring, implantable haemodynamic monitoring devices, co-morbidities including diabetes, anaemia, atrial fibrillation and renal dysfunction and new interventions for acute decompensated heart failure.  


Active programmes for the assessment of heart failure and its optimal management using cardiac impedance, magnetic resonance, computer tomography and advanced electrophysiology are also in place.


Professor Cleland heads The Academic Unit of Cardiology that includes a Reader, 3 Senior Lecturers and a team of basic and clinical scientists, technicians and research nurses dedicated to the above research programme.






Stephane Heymans  

Professor of Cardiomyopathies

Head of the Centre for Heart Failure Research


Maastricht University, Center for Heart Failure Research
Department of Cardiology, Cardiovascular Research Institute Maastricht
P. Debyelaan 25,
6202 AZ, Maastricht,
The Netherlands

Tel: + 31 (0) 43 38 77 097

@ :  This email address is being protected from spambots. You need JavaScript enabled to view it.

Stephane Heymans is Professor of Cardiomyopathies and Head of the Centre for Heart Failure Research, Department of Cardiology, Maastricht University. He obtained his Medical Degree from the KULeuven (Belgium) in 1995 and went on to get a PhD in Medical Sciences in 2000, studying the role of proteinases in acute myocardial infarction. In 2003, He joined the Cardiology Department University Hospital of Maastricht (The Netherlands) as an academic medical specialist and in 2006 he took over the Multidisciplinary Cardiomyopathy Program (Genetics, Immunology, Microbiology and Pathology departments).


In 2008 he established his independent research laboratory at Cardiovascular Research Institute Maastricht. His research interests focus on the molecular mechanisms of heart failure, looking at the interplay between inflammatory cells, fibroblasts and cardiomyocytes. Particular focus is on the role of non-structural matrix proteins, matrix turnover and non-coding RNAs. He is chair of the Strategic Board of the Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Professor of “Inflammation and Matrix Biology in Cardiomyopathies” at the University of Leuven and he is a board member of the ESC Heart Failure Association, ESC Working Group of Myocardial Function, ESC Heart Failure Association Committee on Diastolic Heart Failure and ESC Heart Failure Association Committee on Translational Research.





Roberto Latini, MD
Head of the Cardiovascular Clinical Pharmacology Laboratory


Mario Negri Institue for Pharmacological Research

Department of Cardiovascular Research

Via Giuseppe La Masa, 19

20157 Milano



Phone : +39 02 3901 4454

@ :  This email address is being protected from spambots. You need JavaScript enabled to view it.



Roberto Latini is Head of the Cardiovascular Clinical Pharmacology Laboratory  at the Instituto di Ricerche Farmacologiche “Mario Negri,” in Milan, Italy.  He has been from 2000 to 2008 Visiting Professor, Department of Medicine, at New York Medical College in Valhalla, New York, and is  a member of the GISSI (Italian Study Group on Survival in Myocardial Infarction) Coordinating Center (Istituto Mario Negri, Milano and ANMCO, Firenze, Italy).  Dr. Latini has published numerous articles in peer-reviewed journals in the field of cardiology and is part of the Editorial board of the Journal of Cardiac Failure.  Dr. Latini received his medical degree from the University of Milan School of Medicine.  He was a Cardiology Fellow at Stanford University Medical Center in Stanford, California, as well as a Merck Sharp & Dohme International Fellow in Clinical Pharmacology from 1981 to 1983. He was part of the Steering Committee of GISSI-3 and RESOLVD Pilot. He is at present member of the Steering Committee of the GISSI-HF trial, co-chair of the GISSI-AF trial, and co-chair of the Biologic Committee in the OPERA trial. In Val-HeFT he acted as co-Director of the neurohormone core laboratory and consulted for the Steering Committee of the trial.




Serge Masson, MD
Head of the Cardiovascular Endocrinology Laboratory



Mario Negri Institute for Pharmacological Research 

Department of Cardiovascular Research

Via Giuseppe La Masa, 19

20157 Milano



Phone : +39 02 3901 4615

@ : This email address is being protected from spambots. You need JavaScript enabled to view it.



Serge Masson is a Research Scientist at the Istituto Mario Negri in Milan and Head of the Cardiovascular Endocrinology Unit. He has a PhD in Biochemistry and Molecular Biology. His main research interests focus on cardiac endocrinology, circulating biomarkers, and clinical trials. He has participated to several national and international multicenter clinical trials and epidemiological studies, coordinating biological studies in area like heart failure, atrial fibrillation, diabetes, neurological anesthesia and sepsis. He is coauthor of more than 100 original publications in peer-reviewed scientific journals.





Thomas Thum
Professor, MD, internist, cardiologist
Director of the Institute for Molecular and Translational Therapeutics Strategies (IMTTS)

Hannover Medical School
IFB, Molecular and Translational Therapeutic Strategies
OE 8886
Carl-Neuberg-Str. 1
D-30625 Hannover

Phone : +49 511 532 5272

@ : This email address is being protected from spambots. You need JavaScript enabled to view it.


Prof. Thum studied Medicine at the Hannover Medical School from 1994-2001. In 2008 he received a PhD from the Imperial College in London and finished his Internal and Cardiology Training in 2009/2010. From 2004-2009 he was a physician and scientist at the Julius-Maximilians University in Würzburg, germany. 2009 he became full professor and Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School. Prof. Thum pioneered the therapeutic use of microRNAs in cardiovascular diseases and currently develops both microRNA-based diagnostic and therapeutic strategies to improve cardiovascular diseases especially heart failure.



Jan A. Staessen
Professor of Medicine
Head of Clinic
Head Division of Hypertension and Cardiovascular Rehabilitation

Department of Cardiovascular Diseases
Kapucijnenvoer 35 blok d - box 6702
3000 Leuven

Tel. : +32 16 3 47104 or +32 16 3 47105
Fax : +32 16 3 47106
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.

Jan A. Staessen is Professor of Medicine at the University of Leuven and Head of Clinic at the University Hospitals Leuven. He leads the Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Belgium. In addition, Dr Staessen is Professor of Genetic Epidemiology at the Department of Epidemiology, Maastricht University, Maastricht, the Netherlands.


Dr. Staessen was the principal investigator of influential clinical trials, published in top-ranking journals, such as Systolic Hypertension in Europe Trial (Syst-Eur), the Ambulatory blood Pressure monitoring and Treatment of Hypertension trial (APTH) and the Treatment of hypertension based on Home or Office blood Pressure trial (THOP). He chaired the Data Safety and Monitoring Board of several clinical trials, including the Systolic Hypertension in China trial (Syst-China), the Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP) and the Hypertension in the very Elderly trial (HYVET). He was the scientific coordinator of the Ouabain and Adducin for Specific Intervention on Sodium in HyperTension trial (OASIS-HT). He organised the Newer vs. Older Antihypertensive Agents in African Hypertensive patients (NOAAH) trial, which was running at 6 clinical sites in sub-Saharan Africa and was successfully completed on 31 December 2012.


Dr Staessen is a member of several professional societies, including the International Society of Hypertension, the European Society of Hypertension, the European Society of Cardiology, the American Society of Hypertension, and the American Heart Association. He is past chairperson of the European Hypertension Society Working Group on Blood Pressure Monitoring and is an International Fellow of the Council for High Blood Pressure Research of the American Heart Association. Dr. Staessen has been awarded the title of Doctor Honoris Causa from the Jagiellonian University, Kraków, Poland, one of the oldest and most prestigious universities in Europe. He received several other national and international awards. He is honorary member of the Polish and Spanish Societies of Hypertension.


Dr Staessen’s current research interests focus on the genetics, epidemiology, and treatment of cardiovascular disease, in particular hypertension. In 1998, he started the European Network on Genes in Hypertension (EPOGH). He was on the Steering Committee of the European Network of Excellence INGENIOUS HYPERCARE and the large-scale European research project HYPERGENES. He is currently one of the lead participants in two other FP7 projects, EU-MASCARE and HOMAGE.


Dr Staessen set up two international research consortia: IDACO (International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcome) and IDHOCO (International Database of HOme blood pressure in relation to Cardiovascular Outcome). These networks focus on the clinical applicability of ambulatory blood pressure monitoring or the self-measured blood pressure at home in risk stratification, using data from prospective population studies. In 2011, Dr Staessen received a European Research Council Advanced Researcher grant for population-based research on left ventricular diastolic dysfunction (EPLORE).


Dr. Staessen published over 850 papers (>735 in PubMed) in peer-reviewed journals. Currently, his citation index (excluding own citations) is >15,375 and his H-index is 73. Dr Staessen serves on the editorial board of several top-ranking medical journals. He is an Associate Editor of Hypertension, Hypertension Research, and Blood Pressure Monitoring. He is advisor to The Lancet.





Stuart John Pocock

Department of Medical Statistics
Faculty of Epidemiology and Population Health
London School of Hygiene and Tropical Medicine


Keppel Street
London WC1E 7HT, UK


Tel : +44 20 79 27 24 13
Fax: +44 20 76 37 28 53
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.


Stuart J. Pocock is Professor of Medical Statistics at the London School of Hygiene and Tropical Medicine.


His primary research interest concerns clinical trials, both as regards methodological developments and applied collaboration in major trials.  He also has interests in observational epidemiology especially pharmaco-epidemiology. His particular methodological areas of expertise include: standards for the statistical reporting of trials and epidemiological studies, the statistical ethical and organisational principles for data monitoring including early stopping guidelines, the presentation of time-to-event (survival) data, the pros and cons of non-inferiority trials, problems of multiplicity in trial reporting, eg, subgroup analyses, multiple outcomes and covariate adjustment, the development of prognostic risk scores, and the use/interpretation of meta-analyses.


Professor Pocock runs a statistical centre for the design, conduct, analysis and reporting of major clinical trials, especially in cardiovascular diseases.  He is also a consultant statistician for a wider range of clinical trials in which expert statistical advice is needed, and serves as a statistical member of many trial data monitoring and steering committees.


He collaborates internationally especially with the Centro Nacional de Investigaciones Cardiovasculares in Madrid, and the Cardiovascular Research Foundation and Mount Sinai School of Medicine in New York.  He is a frequent lecturer on a variety of clinical trials issues.


He is Member of the Advisory Board of “Trials”, author of the textbook “Clinical Trials: A Practical Approach”, and Member of the International Advisory Board of The Lancet.


Professor Pocock has published over 300 articles in peer-reviewed journals.





Dr. Javed Butler
Professor of Medicine, Director Heart Failure Research


Cardiology Div, Dept of Medicine

Stony Brook University

Stony Brook, NY 11794-8160



Tel : 
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  

Dr. Javed Butler is Chief of Cardiology and co-Director at Stony Brook Heart Institute. Dr Javed Butler is also Deputy Chief Science Officer for the American Heart Association. After graduating from the Aga Khan University, Dr. Butler completed his residency and chief residency from Yale University, Masters in Public Health from Harvard University, and cardiology fellowship from Vanderbilt University. He subsequently also completed an advanced heart failure and cardiac transplantation fellowship from Vanderbilt University and cardiac Imaging training at the Massachusetts General Hospital. He is board certified in Internal Medicine, Cardiovascular Diseases, Advanced Heart Failure, and Nuclear Cardiology.


He serves various editorial responsibilities for the Journal of the American College of Cardiology, Journal of Cardiac Failure, American Heart Journal, Current Heart Failure Reviews, Heart Failure Clinic, and Congestive Heart Failure. He serves on the American College of Cardiology/American Heart Association as well as the Heart Failure Society of America’s Heart Failure Guidelines Committees. He has published over 150 original research papers. He has served in various committees for multiple professional organizations, the National Institutes of Health, and The Joint Commission. Dr. Butler is the principle investigator for the National Institutes of Health funded Heart Failure Clinical Trials Network at Emory. He has participated in over 50 clinical trials.



Dr. Christian Delles 
Reader and Honorary Consultant Physician


Institute for Cardiovascular and Medical Sciences 

University of Glasgow



Tel : +44 141 330 2749
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  


Christian Delles is a Reader and Consultant Physician at the Institute for Cardiovascular and Medical Sciences, University of Glasgow. After graduating from the University of Freiburg, Germany, and work for his MD Thesis at the University of Innsbruck, Austria, he trained in internal medicine and nephrology at the Department of Nephrology, University of Erlangen-Nürnberg, Germany. He worked in the group of Prof. Roland Schmieder on vascular function in hypertension, diabetes, renal failure and other cardiovascular disorders. In 2003 he was awarded a fellowship by the Deutsche Forschungsgemeinschaft for studies into reactive oxygen species in hypertension in Prof. Anna Dominiczak's group in Glasgow. Christian has been appointed as Senior Lecturer at the University of Glasgow in 2005 and is currently a Reader and Honorary Consultant Physician at the Institute of Cardiovascular and Medical Sciences.


He is interested in the initiation and progression of cardiovascular diseases and studies subclinical organ damage. His research is in the area of vascular biology with oxidative stress and endothelial function as pathogenetic factors of hypertension and other cardiovascular disorders. Currently he focuses on studies into biomarkers of cardiovascular and renal disease with a particular interest in proteomic and systems medicine approaches.


Christian has published more than 110 peer reviewed papers. His research is supported by grants from the European Commission where he is coordinator and/or PI of large consortia including EU-MASCARA, PRIORITY and EURATRANS; the British Heart Foundation; and the Scottish Government.


He is a member of national and international hypertension societies including the Deutsche Hochdruckliga, BHS, ESH, ISH and the Council for High Blood Pressure Research. He is Associate Editor of Clinical Science. He received the Harry Goldblatt Young Investigator Award from the Council for High Blood Pressure Research in 2009. His biomarker research is supported by grants from the European Commission.





2008                                FAHA

2007                                FRCP (Glasg)

1997                                MD University of Feiburg, Germany



2005-2011                        Senior Lecturer & Hon. Consultant Physician, BHF GCRC, Univ. of Glasgow

2003-2005                        Clinical Research Fellow, BHF GCRC, University of Glasgow

1998-2003                        Assistenzarzt, Dept of Medicine IV, University of Erlangen-Nürnberg, Germany





Harald Mischak

Professor, Director of Mosaique Diagnostics GmbH

Mellendorfer Strasse 7-9
30625 Germany 


Tel : 49.511.55.47.440
@ : This email address is being protected from spambots. You need JavaScript enabled to view it.  



Prof. Harald Mischak is general Manager and founder of Mosaiques Diagnostics GmbH, and a worldwode authority in the field of clinical proteome analysis, with more than 190 papers published in peerèreviewed journals and more than 40 patents filed. 



TATAA J Bjorkman  


Jens Björkman

Director Commissioned Service/ Senior Scientists

TATAA Biocenter
Odinsgatan 28
41103 Gothenburg

Tel : + '
Fax : +33 (0)1 55 03 01 60
@ :  This email address is being protected from spambots. You need JavaScript enabled to view it.  



Jens Björkman is Director of Commissioned Services and senior scientist. He holds a MSc in Molecular Biotechnology Engineering from Lund Institute of Technology and 1 patent related to quality control in qPCR. Jens Björkman has extensive experience (10+ years) in the field of qPCR and other associated molecular biology methods, including nucleic acid extraction. He has long experience in management of commissioned service projects, including Proseek® Multiplex analysis (5+ years).